The Effect of Factor Xa Inhibition, With Rivaroxaban, on the Pathology of Sickle Cell Disease

Trial Profile

The Effect of Factor Xa Inhibition, With Rivaroxaban, on the Pathology of Sickle Cell Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Beta-thalassaemia; Sickle cell anaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 May 2018.
    • 27 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 1 May 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top